

Ms Jennifer Jebasundari



Dear Ms Jebasundari

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on 22 September 2020.

I am pleased to confirm the following.

Q1. Could you please provide the numbers of patients treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:

| • | Adalimumab – Humira | 6 patients |
|---|-----------------------|-------------|
| • | Adalimumab Biosimilar | 29 patients |
| • | Apremilast | 14 patients |
| • | Brodalumab | 1 patient |
| • | Certolizumab | 0 patients |
| • | Dimethyl fumarate | 0 patients |
| • | Etanercept – Enbrel | 0 patients |
| • | Etanercept Biosimilar | 0 patients |
| • | Guselkumab | 6 patients |
| • | Infliximab – Remicade | 0 patients |
| • | Infliximab Biosimilar | 0 patients |
| • | Ixekizumab | 2 patients |
| • | Risankizumab | 0 patients |
| • | Secukinumab | 16 patients |
| • | Tildrakizumab | 0 patients |

Ustekinumab 7 patients

As a teaching hospital, we conduct education and research to improve healthcare for our patients. During your visit students may be involved in your care, or you may be asked to participate in a clinical trial. Please speak to your doctor or nurse if you have any concerns. Q2. For the patients treated by the Dermatology department in the last three months with any of the above drugs, can you please provide the total number of paediatric (up to age 16) versus adult patients?

All patients treated were adults.

Q3. Could you please provide the numbers of patients treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:

- Adalimumab Humira 4 patients
- Adalimumab Biosimilar
 81 patients
- Golimumab
 0 patients
- Infliximab Remicade 1 patient
- Infliximab Biosimilar
 85 patients
- Tofacitinib 3 patients
- Ustekinumab
 18 patients
- Vedolizumab
 50 patients

You are advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely,

Freedom of Information Co-ordinator For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the 'Re-use of Public Sector Information Regulations' and best practice.